CICC: Initiates Coverage on I-Mab (02105.HK) with Outperform Rating, Target Price of HK$27.02

Finance and Economics APP learned that Zhongjin released a research report saying that, for the first time covering Lai Kai Medicine-B (02105.HK), they gave it an outperform industry rating with a target price of 27.02 Hong Kong dollars, based on the DCF valuation method, with an upside potential of 43.7% compared to the current stock price. The company is a global biopharmaceutical technology company, focusing on diseases such as metabolism and tumors, and is a newcomer in the domestic fat loss and muscle gain track. The market believes that Bimagrumab from Lilly is strong in data, and the bank believes that it has revealed the drug potential of the ActRII target for fat loss and muscle gain. The company's LAE102 is expected to have differentiated advantages in selectivity, dosing convenience, safety, and other aspects. The bank is optimistic about the potential of international clinical and commercial value unlocking of this pipeline.